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MicroRNAs are a class of negative regulators of gene expression, which have been demonstrated to be involved 
in the development of endocrine pancreas and in the regulation of insulin secretion. Type 2 Diabetes (T2D) is a 
metabolic disease characterized by insulin-resistance in target tissues and by the functional alteration of 
pancreatic insulin-secreting beta-cells. Recently, we characterized the expression levels of microRNAs miR-124a 
and miR-375, both involved in the control of beta cell function, in human pancreatic islets obtained from T2D 
and from age-matched non-diabetic organ donors. We observed the hyperexpression of miR-124a in human 
pancreatic islets obtained from T2D patientsvs non-diabetic subjects, while miR-375 did not result differentially 
expressed. Moreover, we demonstrated that miR-124a overexpression in MIN6-pseudoislets reduced 
glucose-stimulated insulin secretion. Among predicted miR-124a target genes we focused on Foxa2 and Mtpn, 
which are both involved in the regulation of insulin secretion and of glucose sensing. Indeed, using luciferase 
assay, we validated miR-124a targeting Foxa2 and Mtpn 3’UTR sequences. Accordingly, upon miR-124a 
inhibition in MIN6 pseudoislets, we detected the upregulation of Foxa2 and Mtpn and of other selected 
miR-124a predicted target genes such as Akt3, Flot2, Sirt1, and NeuroD1, indicating a possible role for such a 
microRNA in the control of several beta-cell functions. In conclusion, we uncovered a major hyperexpression of 
miR-124a in T2D islets, whose silencing resulted in increased expression of target genes of major importance for 
beta cell function and whose overexpression impaired glucose stimulated insulin secretion, leading to the 
hypothesis that an altered miR-124a expression may contribute to beta cell dysfunction in type 2 diabetes. 
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MicroRNAs are a class of small endogenous RNAs, 19-23 
nucleotides long, which negatively regulate gene expression 
[1]. They specifically bind to the 3’UTR (UnTranslated 
Region) of mRNA by a sequence-dependent mechanism, and 
act as suppressors of mRNA translation or by sequestering 
their targets to specific cytoplasmic loci, leading to mRNA 
degradation [2].  
During the last decade, microRNAs have been widely 
associated to the regulation of several biological processes 
such as cell cycle, apoptosis, cell differentiation or 
embryonic development, through the modulation of pivotal 
factors, involved in these phenomena [3, 4]. Since microRNAs 
can control post-transcriptional expression of genes involved 
in such important biological pathways, alterations of their 
expression may lead to major defects in several cellular 
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functions. Indeed, changes in microRNA expression have 
been reported in many diseases such as cancer, autoimmune 
and metabolic disorders, including type 1 (T1D) and type 2 
diabetes (T2D) [5, 6]. 
T2D is a metabolic disease characterized by target tissues 
insulin-resistance and by functional alterations of pancreatic 
insulin-secreting beta-cells, leading to chronic elevation of 
blood glucose levels (hyperglycaemia). In insulin-resistant 
individuals, a reduced beta-cell mass as well as a defective 
insulin–secretory machinery contribute to the lack of 
compensatory beta-cell response and, consequently, to 
diabetes development [7, 8].  
Recently, several studies focused on the role of 
microRNAs as regulators of beta-cell functions both in 
healthy conditions and in diabetes [9,10]. The major evidence 
of the role of microRNAs in insulin secreting cells has been 
uncovered by specifically deleting Dicer1 enzyme in mouse 
beta-cells, thus rendering these cells incapable of 
synthesizing microRNAs. Indeed, RIP-CRE Dicer1-KO mice 
have been reported to become progressively hyperglycemic 
and finally to develop diabetes. Moreover, these mice display 
impaired insulin biosynthesis and secretion as well as 
abnormal number and size of pancreatic islets [11]. These data 
indicate an essential role of microRNA-mediated regulation 
of beta-cell mass and functions.  
One of the first microRNAs shown to regulate beta-cell 
functional pathways was reported by the group of Poy M in 
2007 [12], with the identification of a microRNA, miR-375, 
specifically and highly expressed in human and mouse 
pancreatic islets. In addition, these authors reported a specific 
role for this microRNA in the regulation of insulin secretion. 
Indeed, miR-375 was able to specifically inhibit 
glucose-induced insulin secretion by targeting Myotrophin 
(Mtpn), a protein involved in remodeling of F-actin filaments 
and in secretory granules exocytosis. Recent evidence 
demonstrated that miR-375 is not only involved in insulin 
secretion but also in the control of beta-cell proliferation and 
mass. Moreover, it has been shown that miR-375-KO mice 
are hyperglycemic and exhibit a reduced beta-cell mass, as a 
result of impaired proliferation. It was demonstrated that 
these effects were mainly due to the loss of miR-375 in the 
control of the expression of a cluster of genes, which 
negatively regulate cell growth and proliferation [13]. 
Moreover, the activity of miR-375 has also been linked to the 
control of pancreas development and of beta-cell 
differentiation as well as beta-cell proliferation and insulin 
secretion [14, 15].  
Together with miR-375, other microRNAs have been 
reported to have a major role in the regulation pancreatic islet 
functions. Among them, microRNA miR-124a was identified 
as a regulator of both insulin secretion and of beta-cell 
development [16].  
MicroRNA miR-124a, together with miR-9, has been 
firstly characterized as a promoter of neural-lineage 
differentiation [17]. Such microRNAs were initially identified 
as brain-specific factors, which mainly regulate neurogenesis 
and neural functions. Later, miR-124a and miR-9 were also 
linked to the control of insulin secretion and of beta-cell 
development both in mouse and in man. In 2007, Baroukhet 
al. reported for the first time a specific role of miR-124a in 
pancreas development and in beta-cell functional regulation 
[18], describing an increased expression of miR-124a during 
mouse embryonic pancreas development, thus indicating a 
possible role for such microRNA in the control of pancreas 
organogenesis. Moreover, they analyzed miR-124a potential 
target genes involved in beta-cell development or in beta-cell 
function; among several target genes, they focused on Foxa2, 
a major beta-cell transcription factor which regulates both 
beta-cell differentiation and insulin secretion. A specific 
targeting of miR-124a on Foxa2 gene, which in turn 
regulates insulin secretion, was demonstrated, thus 
suggesting a role for this microRNA in beta-cell activity. 
Although several investigations have focused on the role 
of microRNAs in T2D animal models or in mechanistic 
evaluation of their function in murine beta-cell lines, only 
few studies analyzed differential microRNA expression in 
human pancreatic islets from T2D patientsvs non-diabetic 
subjects. This was mainly due to the limited availability of 
islet preparations, especially from type 2 diabetic patients. 
Another important issue is the heterogeneity among T2D 
multiorgan donors and the high variability of microRNA 
expression due to several factors such as age, body mass 
index (BMI) or type of anti-hyperglycemic treatment [19].  
The paucity of data on microRNAs expression in human 
pancreatic islets in T2D and the importance of miR-375 and 
miR-124a in the regulation of several beta-cell functions, 
prompted us to analyze their expression in T2D vs 
non-diabetic human pancreatic islets [20]. In this study, we 
reported the analysis of miR-124a and miR-375 expression in 
human pancreatic islets from 6 non-diabetic and 5 T2D 
multiorgan donors using stem-loop RT Real Time PCR. 
Interestingly, we detected a significant upregulation of 
miR-124a in T2D islets respect to control donors; in contrast, 
no differential expression of miR-375 was observed. In 
addition, the expression levels of miR-124a in non-diabetic 
pancreatic islets resulted extremely low in comparison with 
that of several other pancreatic islet microRNAs, suggesting 
the need to maintain low miR-124a expression levels in adult 
human pancreatic islet cells for proper islet function. 
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Consequently, hyperexpression of miR-124a that we reported 
in T2D islets may contribute to the development and/or to the 
progression of beta-cell dysfunction (e.g. reduced 
glucose-stimulated insulin secretion, increased apoptosis, 
reduced islet neogenesis,).  
In our study miR-124a expression levels in T2D 
pancreatic islets did not correlate with age or BMI nor its 
expression was increased upon high glucose exposure as 
evidenced by in-vitro treatment of non-diabetic human 
pancreatic islets, indicating that factors other than 
hyperglycemia determine the hyper-expression of this 
microRNA in T2D islets. 
Only few studies were performed on microRNA profiles 
analysis in T2D, with some reporting differential expression 
of a series of microRNAs in human pancreatic islets. A 
recent study published by Bolmesonet al. described the 
differential expression of several microRNAs in human 
pancreatic islets obtained from glucose intolerant subjects 
[21]. They analyzed specific microRNAs chosen from an 
initial selection of those most highly expressed in 
non-diabetic human pancreatic islets. Among differentially 
expressed microRNAs, they identified the upregulation of 
miR-375, while did not select miR-124a for further analyses. 
In another study, Kameswaranet al. described small RNAs 
analysis profile of T2D pancreatic islets versus non-diabetic 
controls using RNA sequencing [22]. They did not report any 
differential expression of miR-124a in T2D donors; however, 
this might be due to the low expression of miR-124a in 
non-diabetic islets and to the relatively high stringency of 
RNA-seq when selecting candidate small RNAs 
differentially expressed. These discrepancies among different 
studies might be also attributed to the heterogeneity of 
patient cohorts analyzed. The data generated by 
Kameswaranet al. seem to be discordant also from those of 
Tattikotaet al[23] who reported the down-regulation of 
miR-184 in T2D islets (measured by RT-PCR), while no 
differential expression regarding this microRNA was 
observed in Kameswaran study. 
MiR-124a effect(s) on beta-cell functions have been 
partially characterized by several authors [16]. Indeed, 
previous studies highlighted a pivotal role for miR-124a in 
the control of insulin granules exocytosis and of glucose 
sensing machinery. We confirmed that overexpression of 
miR-124a in MIN6-pseudoislets inhibits glucose-stimulated 
insulin secretion (16.7mM glucose) while it does not affect 
insulin secretion at lower glucose (3.3 mM) levels. This 
effect appears to be mediated by the combined 
downregulation of miR-124a target genes, Foxa2 and Mtpn. 
Foxa2 exerts its effect through the regulation of 
Kcnj11(potassium channel, inwardly rectifying subfamily J, 
member 11) and Abcc8(ATP-binding cassette, sub-family C 
(CFTR/MRP), member 8) genes, the subunits of the 
ATP-dependent K (KATP) channel, while Mtpn regulates 
trafficking of insulin granules and their docking to the 
plasma membrane. Using luciferase-reporter assays, we 
confirmed the direct binding of miR-124a to the 3’UTR of 
both Foxa2 and Mtpn genes; specifically, luciferase activity 
controlled by Foxa2 and by Mtpn 3’UTR was decreased 
upon miR-124a overexpression. Accordingly, by mutating 
miR-124a binding sequences within 3’UTR of Foxa2 and 
Mtpn genes, we observed a restoration of luciferase activity, 
indicating a specific activity of miR-124a in the 3’UTR of 
these genes. Moreover, we observed an upregulation of 
Foxa2 and Mtpn expression following miR-124a inhibition 
in MIN6-pseudoislets, indicating that miR-124a negatively 
regulates their expression. In the light of miR-124a increased 
expression reported in T2D islets, these data suggest a 
possible role for this microRNA in the downregulation of 
Foxa2 and of Mtpn expression in T2D pancreatic islets, thus 
contributing to impaired insulin secretion and defective 
glucose sensing machinery.  
In addition, although miR-124a negatively regulates 
Foxa2 and Mtpn, we cannot rule out that its effects on 
pancreatic islets may also be mediated by additional target 
genes (Figure 1). To this end, we looked for any predicted 
miR-124a target gene, which may be involved in beta-cell 
functions, besides insulin secretion and glucose-sensing 
mechanisms. The recently developed microRNA prediction 
algorithms allowed us to identify additional putative 
miR-124a target genes with fundamental functions within 
beta-cell. Namely we detected: Akt3, Sirt1, Flot2 and 
NeuroD1/Beta2 [24-27]. These miR-124a target genes showed 
increased expression upon miR-124a inhibition in 
MIN6-pseudoislets, indicating direct or indirect effect(s) of 
this microRNA in the regulation of their expression. 
Luciferase assays on 3’UTR will clarify whether such 
regulation is directly mediated by miR-124a or not. The 
upregulation of miR-124a observed in pancreatic islets from 
T2D organ donors may lead to a decreased expression of its 
target genes with effects on islet functions depending on the 
specific gene targeted. For example, decreased expression of 
NeuroD1, a transcription factor involved in insulin gene 
transcription, may lead to decreased insulin biosynthesis [28]. 
NeuroD1 is also involved in the regulation of several genes, 
which control the identity of beta-cell. Loss of phenotype 
specification (or dedifferentiation) has been recently 
proposed as a possible cause of beta-cell dysfunction in T2D 
[29]. We may speculate that upregulation of miR-124a leads to 
downregulation of NeuroD1, thus enhancing or favoring 
dedifferentiation phenomena. Disruption of insulin signaling 
through down-regulation of Akt3 or of Flot2 may represent 
other putative mechanisms of beta cell dysfunction: a not 
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fully efficient insulin/insulin growth factor signaling has 
been reported to induce an impaired beta-cell response in 
insulin resistance, secondary to a lack of compensatory 
response in terms of proliferation and growth [31]. Finally, 
Sirt1, a NAD-dependent deacetylase involved in metabolic 
control of cell survival and in insulin secretion, may also be 
downregulated by miR-124a, thus potentially contributing to 
decreased insulin response to glucose and/or to a reduced 
beta-cell survival.  
Another interesting aspect of miR-124a hyperexpression 
in T2D human pancreatic islets is represented by the cause(s) 
of such hyperexpression. In our study we could rule out the 
contribution of age, sex, BMI or hyperglycemia. Of note, 
specific polymorphisms related to miR-124a gene sequence 
and/or flanking gene sequences might contribute to the 
observed effect. A recent study revealed a specific 
polymorphism of miR-124a gene (C/G rs531564) in a cohort 
of T2D patients [30]. This SNP has been detected outside the 
mature miR-124a seed region DNA sequence, more 
specifically in the pre-miR sequence. The G allele of 
rs531564 in hsa-miR-124a gene appears to be a risk allele 
(OR = 2.15, P = 0.008), which confers a specific detrimental 
phenotype to beta-cells. Indeed, a previous study reported 
that the G allele produces a pre-miR-124a secondary 
structure different from that of the C allele, changing the 
conformation of the stem-loop shaped structure and thus 
leading to changes in pre-miR stability [32]. Moreover, it was 
observed that the G allele is associated to increased 
expression of miR-124a, which is in line with our findings.  
Overall, emerging data suggest that miR-124a is 
hyperexpressed in pancreatic islets from T2D multiorgan 
donors respect to non-diabetic subjects and that it may be 
involved in beta-cell dysfunction. We hypothesize a specific 
role of miR-124a in the regulation of insulin secretion and of 
glucose sensing machinery, suggesting a potential 
involvement of islet miR-124a hyperexpression in beta-cell 
dysfunction in T2D. Indeed, as previously published, we 
confirmed miR-124a role in the control of two master gene 
regulators of insulin secretion (Foxa2 and Mtpn) and shed 
light on new possible miR-124a target genes (Flot2, 
NeuroD1, Akt3 and Sirt1) with a pivotal role in beta-cell 
functional control. Although further studies are required to 
fully understand the role of miR-124a in human pancreatic 
islets, accumulating evidence indicates that altered 
expression of specific microRNAs, including miR-124a, may 
contribute to the pathogenesis of T2D. 
Figure1.MicroRNA miR-124a negatively regulates the expression of multiple genes in insulin-secreting 
cells. MicroRNA miR-124a is hyperexpressed in T2D human pancreatic islets and targets several genes involved in 
beta-cell function. Foxa2 and Mtpn genes (highlighted in the red boxes) are experimentally validated targets, while 
Akt3, Sirt1, Flot2 and Neurod1 are predicted targets. All reported genes showed increased expression levels upon 
miR-124a inhibition in MIN6 pseudoislets leading us to hypothesize the downregulation of these target genes 
caused by miR-124a hyperexpression in human pancreatic islets from T2D donors. 
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